Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

Alcon (ALC) announced the U.S. launch of SYSTANE PRO Preservative-Free PF as the latest over-the-counter eye drop in the company’s dry eye portfolio. SYSTANE PRO PF is the longest lasting eye ...

Mizuho raised the firm’s price target on Alcon (ALC) to $120 from $115 and keeps an Outperform rating on the shares following the capital ...

Alcon has acquired a majority interest in Aurion Biotech, according to a press release. Aurion will operate as a separate ...

And in our experience, buying the right stocks can give your wealth a significant boost. To wit, the Alcon share price has climbed 78% in five years, easily topping the market return of 33% ...

Deerfield Management accused Alcon of obstructing Aurion’s IPO plans so it could acquire the startup “at a discount.” ...

Alcon will expand its femtosecond laser-assisted cataract surgery offerings with a deal to acquire Lensar, according to a ...

The acquisition will include Lensar’s ALLY Robotic Cataract Laser Treatment System and Streamline software technology.

The companies will come together to advance robotic laser technology in cataract surgery; improving precision, reducing patient comfort, and providing faster recovery time. Read on to find out ...

Alcon announced today that it entered into a definitive merger agreement through which it intends to acquire Lensar.